Effect of plerixafor plus G-CSF on tumour cell mobilisation in patients with multiple myeloma

被引：0
|
作者：
Fruehauf, S. [1 ]
Topaly, J. [1 ]
Muller, S. [1 ]
Moos, M. [1 ]
Goldschmidt, H. [1 ]
Ho, A. D. [1 ]
Calandra, G. [2 ]
机构：
[1] Univ Heidelberg, Heidelberg, DE, Germany
[2] Genzyme Corp, Cambridge, MA USA
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [1] Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma
    Nazha, Aziz
    Cook, Rachel
    Vogl, Dan T.
    Mangan, Patricia A.
    Hummel, Kimberly
    Cunningham, Kathleen
    Luger, Selina
    Porter, David
    Schuster, Stephen J.
    O'Doherty, Una
    Sell, Mary
    Siegel, Don L.
    Stadtmauer, Edward A.
    BLOOD, 2009, 114 (22) : 844 - 844
  • [2] Vinorelbine and cyclophosphamide plus G-CSF as mobilisation regimen for patients with multiple myeloma
    Palmieri, S
    Pocali, B
    Copia, C
    Schiavone, EM
    Annunziata, M
    Viola, A
    Ferrara, F
    BONE MARROW TRANSPLANTATION, 2004, 33 : S354 - S354
  • [3] A Comparison of Chemotherapy plus G-CSF Versus Plerixafor (Mazobil®) plus G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide.
    Mark, Tomer M.
    Rossi, Adriana C.
    Pearse, Roger N.
    Coleman, Morton
    Bernstein, David
    Zafar, Faiza
    Dergis, Usama
    Shore, Tsiporah B.
    Niesvizky, Ruben
    BLOOD, 2010, 116 (21) : 928 - 929
  • [4] EFFICACY OF PLERIXAFOR PLUS G-CSF FOR STEM CELL MOBILISATION IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA WHO HAVE FAILED PRIOR MOBILISATION - A NAMED PATIENT PROGRAM [NPP] EVALUATION
    Apperley, F.
    Cook, G.
    Pagliuca, A.
    Stringaris, K.
    Douglas, K.
    Pozo, A.
    Wilson, K.
    Davies, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 212 - 212
  • [5] Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
    Afifi, S.
    Adel, N. G.
    Devlin, S.
    Duck, E.
    Vanak, J.
    Landau, H.
    Chung, D. J.
    Lendvai, N.
    Lesokhin, A.
    Korde, N.
    Reich, L.
    Landgren, O.
    Giralt, S.
    Hassoun, H.
    BONE MARROW TRANSPLANTATION, 2016, 51 (04) : 546 - 552
  • [6] Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
    S Afifi
    N G Adel
    S Devlin
    E Duck
    J Vanak
    H Landau
    D J Chung
    N Lendvai
    A Lesokhin
    N Korde
    L Reich
    O Landgren
    S Giralt
    H Hassoun
    Bone Marrow Transplantation, 2016, 51 : 546 - 552
  • [7] G-CSF Plus Preemptive Plerixafor Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma: Effectiveness, Safety and Cost Analysis
    Antar, Ahmad
    Otrock, Zaher
    Kharfan-Dabaja, Mohamed
    Abou Ghaddara, Hussein
    Kreidieh, Nabila
    Mahfouz, Rami
    Bazarbachi, Ali
    BLOOD, 2014, 124 (21)
  • [8] IS LOW DOSE CYCLOPHOSPHAMIDE PLUS G-CSF MOBLIZATION AS EFFECTIVE AS MOZOBIL (PLERIXAFOR) PLUS G-CSF IN MULTIPLE MYELOMA (MM) PATIENTS ELIGIBLE FOR TANDEM TRANSPLANT?
    Karanes, C.
    Dagis, A.
    Wang, S.
    Krishnan, A.
    Sahebi, F.
    Popplewell, L.
    Parker, P.
    Forman, S.
    Palmer, J.
    Kogut, N.
    Somlo, G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S205 - S206
  • [9] Stem Cell Mobilization With Plerixafor plus G-CSF In Comparison To Cyclophosphamide plus G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma
    Garfall, Alfred L.
    Dougherty, Andrew
    Vogl, Dan T.
    Weiss, Brendan M.
    Cohen, Adam D.
    Porter, David L.
    O'Doherty, Una
    Mangan, Patricia
    Cunningham, Kathleen
    Siegel, Don L.
    Stadtmauer, Edward A.
    BLOOD, 2013, 122 (21)
  • [10] G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis
    A Antar
    Z K Otrock
    M A Kharfan-Dabaja
    H A Ghaddara
    N Kreidieh
    R Mahfouz
    A Bazarbachi
    Bone Marrow Transplantation, 2015, 50 : 813 - 817
12345